Health and Me on MSN3d
You Have Heard Of Blood Thinning, But Do You Know Blood Thickening Can Also Make You Sick?
Blood thickening, or hypercoagulability, occurs when excess cells or clotting proteins make blood more viscous, increasing ...
MPR3d
Rusfertide Improves Hematocrit Control in Patients With Polycythemia Vera
Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equity ...
The American Journal of Managed Care4d
Managing Polycythemia Vera to Reduce Risks and Improve Lives
Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to ...
Essential Thrombocythemia Market To Witness Upsurge In Growth During The Study Period (2020–2034) | Delveinsight
The essential thrombocythemia market is expected to grow steadily due to increasing disease prevalence, advancements in targeted therapies, and risin ...
BioWorld5d
Protagonist’s rusfertide hits phase III goals in rare leukemia
Rusfertide could become a blockbuster therapy for polycythemia vera, H.C. Wainwright analyst Douglas Tsao wrote March 4 after the injectable hepcidin mimetic peptide hit its primary endpoint and all ...
The Pharma Letter5d
Positive Phase III VERIFY results of rusfertide in PV
US clinical-stage pharma company Protagonist Therapeutics and Japan’s Takeda have announced positive top-line results for the ...
Protagonist Therapeutics price target raised to $57 from $53 at JPMorgan
JPMorgan raised the firm’s price target on Protagonist Therapeutics (PTGX) to $57 from $53 and keeps an Overweight rating on the shares. The ...
Protagonist And Takeda Announce Positive Topline Results From Phase 3 VERIFY Study Of Rusfertide In Patients With Polycy...
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...
BioPharma Dive6d
Protagonist says Takeda-partnered drug succeeds in rare blood cancer
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...
CURE6d
Rusfertide Elicits Promising Responses in Polycythemia Vera
Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...